The Role of Next-Generation Sequencing in the Management of Patients with Suspected Non-Ischemic Cardiomyopathy after Syncope or Termination of Sudden Arrhythmic Death
Genes · 2024
DOI: 10.3390/genes15010072 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes, 2024. Verfasst von Damijan Vokač und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology and Angiology, Division of Internal Medicine, University Medical Centre Maribor, 2000 Maribor, Slovenia. Hauptthemen laut MEDLINE: Heart Diseases, Heart Failure. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University Medical Centre Maribor, Maribor, Slovenia, ARIS, Slovenia, Innovation Agency (ARIS), Ljubljana, Slovenia.
Abstract (Originalsprache)
Cardiac arrhythmias and sudden death are frequent in patients with non-ischemic cardiomyopathy and can precede heart failure or additional symptoms where malignant cardiac arrhythmias are mostly the consequence of advanced cardiomyopathy and heart failure. Finding these subgroups and making an early diagnosis could be lifesaving. In our retrospective study, we are presenting arrhythmic types of frequent cardiomyopathies where an arrhythmogenic substrate is less well defined, as in ischemic or structural heart disease. In the period of 2 years, next-generation sequencing (NGS) tests along with standard clinical tests were performed in 208 patients (67 women and 141 men; mean age, 51.2 ± 19.4 years) without ischemic or an overt structural heart disease after syncope or aborted sudden cardiac death. Genetic variants were detected in 34.4% of the study population, with a significant proportion of pathogenic variants (P) (14.4%) and variants of unknown significance (VUS) (20%). Regardless of genotype, all patients were stratified according to clinical guidelines for aggressive treatment of sudden cardiac death with an implantable cardioverter defibrillator (ICD). The P variant identified by NGS serves for an accurate diagnosis and, thus, better prevention and specific treatment of patients and their relatives. Results in our study suggest that targeted sequencing of genes associated with cardiovascular disease is an important addendum for final diagnosis, allowing the identification of a molecular genetic cause in a vast proportion of patients for a definitive diagnosis and a more specific way of treatment. VUS in this target population poses a high risk and should be considered possibly pathogenic in reanalysis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology and Angiology, Division of Internal Medicine, University Medical Centre Maribor, 2000 Maribor, Slovenia.
- Clinical Institute for Genetic Diagnostics, University Medical Centre Maribor, 2000 Maribor, Slovenia.
- Medical Faculty, University of Maribor, 2000 Maribor, Slovenia.
Förderung
- University Medical Centre Maribor, Maribor, Slovenia
- ARIS, Slovenia
- Innovation Agency (ARIS), Ljubljana, Slovenia
Zitieren
APA
Vokač, D., Stangler Herodež, Š., Krgović, D., & Kokalj Vokač, N. (2024). The Role of Next-Generation Sequencing in the Management of Patients with Suspected Non-Ischemic Cardiomyopathy after Syncope or Termination of Sudden Arrhythmic Death. Genes. https://doi.org/10.3390/genes15010072
Vancouver
Vokač D, Stangler Herodež Š, Krgović D, Kokalj Vokač N. The Role of Next-Generation Sequencing in the Management of Patients with Suspected Non-Ischemic Cardiomyopathy after Syncope or Termination of Sudden Arrhythmic Death. Genes. 2024. doi:10.3390/genes15010072
BibTeX
@article{Voka2024,
author = {Vokač, Damijan and Stangler Herodež, Špela and Krgović, Danijela and Kokalj Vokač, Nadja},
title = {The Role of Next-Generation Sequencing in the Management of Patients with Suspected Non-Ischemic Cardiomyopathy after Syncope or Termination of Sudden Arrhythmic Death},
journal = {Genes},
year = {2024},
doi = {10.3390/genes15010072}
}
EUVIMED